Cover Image
市場調查報告書

OpportunityAnalyzer:移植物抗宿主病(GVHD)- 機會分析與預測

OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2023

出版商 GlobalData 商品編碼 310940
出版日期 內容資訊 英文 260 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:移植物抗宿主病(GVHD)- 機會分析與預測 OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2023
出版日期: 2015年12月01日 內容資訊: 英文 260 Pages
簡介

主要6個國家(美國、法國、德國、義大利、西班牙、英國)的移植物抗宿主病(GVHD)的治療藥市場,從2013年的2億9,700萬美元,預計到2018年擴大到4億900萬美元規模,以CAGR6.61%增加。

本報告提供移植物抗宿主病(GVHD)的治療藥市場相關調查分析、疾病概要、流行病學、目前治療選項、未滿足需求和機會、研究開發策略、開發平台評估等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 確診的發病數量:造血幹細胞移植(HSCT)
    • 確診的發病數量:自體HSCT
    • 確診的發病數量:同種異體HSCT
    • 確診的發病數量:急性移植物抗宿主病(aGVHD)
    • 確診的4年患病數量:aGVHD
    • 確診的發病數量:慢性移植物抗宿主病(cGVHD)
    • 確診的5年患病數量:cGVHD
  • 移植物抗宿主病(GVHD)的流行病學預測
    • 確診的發病數量:造血幹細胞移植(HSCT)
    • 確診的發病數量:自體HSCT
    • 確診的發病數量:同種異體HSCT
    • 確診的發病數量:急性移植物抗宿主病(aGVHD)
    • 確診的4年患病數量:aGVHD
    • 確診的發病數量:慢性移植物抗宿主病(cGVHD)
    • 確診的5年患病人數:cGVHD
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 目前治療選項

  • 概要
  • 產品簡介:主要的治療藥
  • 產品簡介:非標籤藥物治療藥

第6章 未滿足需求和機會

  • 概要
  • 非人為化臨床試驗(RCT)的缺乏
  • 臨床試驗評估項目相關不一致
  • 預防對策的最佳化
  • 缺乏現有/非標籤藥物治療藥的標準通訊協定
  • 毒性發病的患者的治療結果的改善
  • 對顯示長期有效性的治療的要求
  • 類固醇抗性aGVHD患者的管理
  • 硬化性cGVHD患者的管理
  • 肺病變伴隨的患者預後的提高

第7章 研究開發(R&D)策略

  • 概要
  • 目前臨床試驗設計
  • 未來的臨床試驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發中的有前途藥物
  • 創新的初期階段的方法

第9章 開發平台/非標籤藥物的評估分析

  • 主要開發平台/非標籤藥物藥臨床基準
  • 主要開發平台/非標籤藥物藥的商業基準
  • 競爭評估
  • 銷售額的5年預測
    • 美國
    • EU5個國家

第10章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC014EPOA

The main drivers of growth in graft versus host disease over the 2013-2023 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.

Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. J&J's Remicade, has gained a significant patent share of the aGVHD patient group, as it is one of the few drugs that are efficient in GVHD with GI involvement. Gaining more and more ground in the treatment management of cGVHD is Roche's Rituxan that GlobalData estimates will be one of the bestselling biologics in GVHD in the US by 2023.

Despite the vast array of available off-label therapies for the treatment and/or prevention of GVHD, very few of these therapies have been tested in large randomized trials. This results in vague treatment recommendations and many patients being enrolled in institutional clinical trials. The only available standard of care is intravenous methylprednisolone that fails to produce a complete response in more than 50% of treated patients. Steroid-refractory subgroups face low prognosis with deteriorating quality of life. Second and third life treatments can vary from country to country but also between different medical institutions in the same country.

The GVHD market was valued at $297.0m across the 6MM in 2013, and is expected to increase to $544.4m in 2023, at a Compound Annual Growth Rate (CAGR) of 12.84%.

Highlights

Key Questions Answered

  • How will the GVHD market landscape change within the 2013-2023 forecast period in the 6MM?
  • What are the most promising late-stage pipeline drugs in GVHD?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
  • What are the unmet needs in GVHD treatment management?
  • What needs to change in the GVHD R&D and treatment guidelines settings?

Key Findings

  • High uptake of off-label biologics (Rituxan, Lemtrada, Remicade and Thymoglobuline)
  • No national guidelines are in place
  • GVHD remains a field of highly unattained unmet need
  • No consensus over clinical trial endpoints
  • Regulatory T cells (Tregs) are the focus of the early stage pipeline
  • Huge opportunity exists in the chronic patient segment of GVHD
  • Institutionally funded studies are the core of GVHD treatment management

Scope

  • Overview of GVHD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
  • Annualized GVHD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2023.
  • Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the GVHD therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including TNF blockers, CD25a blockers, GVHD-specific therapies etc.
  • Analysis of the current and future market competition in the US and five major EU GVHD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Reasons to buy

The report will enable you to -

  • Identify the unmet needs and remaining opportunities in the GVHD therapeutics market.
  • Develop business strategies by understanding the trends shaping and driving the US and five major EU GVHD therapeutics market.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Assess the clinical and commercial viability of promising pipeline products.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU GVHD therapeutics market in future.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Classification and Prognosis
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Diagnosed Incident Cases of HSCTs
    • 4.4.4. Diagnosed Incident Cases of Autologous HSCTs
    • 4.4.5. Diagnosed Incident Cases of Allogeneic HSCTs
    • 4.4.6. Diagnosed Incident Cases of aGVHD
    • 4.4.7. Four-Year Diagnosed Prevalent Cases of aGVHD
    • 4.4.8. Diagnosed Incident Cases of cGVHD
    • 4.4.9. Five-Year Diagnosed Prevalent Cases of cGVHD
  • 4.5. Epidemiological Forecast for GVHD (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of HSCTs
    • 4.5.2. Diagnosed Incident Cases of Autologous HSCTs
    • 4.5.3. Diagnosed Incident Cases of Allogeneic HSCTs
    • 4.5.4. Diagnosed Incident Cases of aGVHD
    • 4.5.5. Four-Year Diagnosed Prevalent Cases of aGVHD
    • 4.5.6. Diagnosed Incident Cases of cGVHD
    • 4.5.7. Five-Year Diagnosed Prevalent Cases of cGVHD
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles - Major Therapies
    • 5.2.1. Methylprednisolone (numerous brand and generic names)
    • 5.2.2. Cyclosporine (numerous brands and generic names)
    • 5.2.3. Anti-Thymocyte Globulin (ATG) Therapies
  • 5.3. Product Profiles - Off-Label Therapies
    • 5.3.1. Biologics (Tumor Necrosis Factor (TNF)α Inhibitors, Interleukin-2 Receptor α (CD25) Inhibitors, Co-Stimulatory Blockers and Other Biologics)
    • 5.3.2. Small Immunosuppressive Molecules (mTOR Inhibitors, Solid Organ Transplant Therapies, and Anti-Neoplastic Therapies)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Lack of Randomized Clinical Trials
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. No Consensus Regarding Clinical Trial Endpoints
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Optimization of Prophylactic Measures
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Lack of Standardized Protocols for Established and Off-Label Therapies
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Treatment Outcomes for Patients Who Develop Toxicities
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Desire for Treatments that Exhibit Longer-Lasting Efficacy Profiles
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Management of SR-aGVHD Patients
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity
  • 6.9. Management of Sclerotic cGVHD Patients
    • 6.9.1. Unmet Need
    • 6.9.2. Gap Analysis
    • 6.9.3. Opportunity
  • 6.10. Improved Prognosis for Patients with Lung Involvement
    • 6.10.1. Unmet Need
    • 6.10.2. Gap Analysis
    • 6.10.3. Opportunity

7. Research and Development Strategies

  • 7.1. Overview
    • 7.1.1. Improvement of Prophylactic Regimens
    • 7.1.2. Inhibition of T-Cell Proliferation and Activation
    • 7.1.3. Adopting Treatments from Hematologic Indications
    • 7.1.4. Targeting Niche Subgroups Within GVHD
  • 7.2. Current Clinical Trial Design
    • 7.2.1. Current Trial Designs are Dependent on the Stage Within the Treatment Algorithm That a Product is Targeting
    • 7.2.2. Lack of Consensus on Clinical Endpoints in Current Trial Designs
    • 7.2.3. Patient Exclusion Issues in Current Trial Designs
    • 7.2.4. Current Trial Design of Key Pipeline Products
  • 7.3. Future Clinical Trial Design
    • 7.3.1. Future Trial Designs Need to Incorporate Randomization
    • 7.3.2. Future Trial Designs Need to Incorporate Conditioning Regimens and Hematological Patients
    • 7.3.3. Companies Behind Off-Label Therapies Should Strategize to Conduct Randomized Studies
    • 7.3.4. Companies with Pipeline Assets Targeting GVHD must invest in Biomarkers
    • 7.3.5. Design of Early-Phase Clinical Trials for Cellular and Gene Therapy Products Accommodates 2014 Guidance from the FDA

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Leukotac (inolimomab)
    • 8.2.2. Begedina (BT 5/9)
    • 8.2.3. Budenofalk (budesonide)
    • 8.2.4. ATG-Fresenius (EZ-2053)
    • 8.2.5. Prochymal (remestemcel-L)
    • 8.2.6. MultiStem (modified mesenchymal stem cells)
    • 8.2.7. Uvadex (Extracorporeal Photophoresis)
    • 8.2.8. orBec (beclomethasone dipropionate)
  • 8.3. Innovative Early-Stage Approaches
    • 8.3.1. Targeting Regulatory T Cells
    • 8.3.2. Mesenchymal Stem Cell Therapies
    • 8.3.3. Immunomodulatory Cell Surface Receptor Inhibitors
    • 8.3.4. IL-6 Inhibitors

9. Pipeline and Off-Label Valuation Analysis

  • 9.1. Clinical Benchmarking of Key Pipeline and Off-Label Drugs
    • 9.1.1. GVHD Prophylaxis
    • 9.1.2. Acute GVHD
    • 9.1.3. Chronic GVHD
  • 9.2. Commercial Benchmarking of Key Pipeline and Off-Label Drugs
    • 9.2.1. GVHD Prophylaxis
    • 9.2.2. Acute GVHD
    • 9.2.3. Chronic GVHD
  • 9.3. Competitive Assessment
    • 9.3.1. GVHD Prophylaxis
    • 9.3.2. Acute GVHD
    • 9.3.3. Chronic GVHD
  • 9.4. Top-Line Ten-Year forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed GVHD Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in This Study
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Reviewer
    • 10.6.3. Epidemiologist
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Steps Involved in the Development of aGVHD
  • Table 2: Steps Involved in the Development of cGVHD
  • Table 3: Grading System of Organ Involvement in aGVHD
  • Table 4: Classification of Organ Involvement in cGVHD
  • Table 5: Symptoms of aGVHD
  • Table 6: Symptoms of cGVHD
  • Table 7: Risk Factors and Comorbidities for GVHD
  • Table 8: 6MM, Sources of HSCT, aGVHD, and cGVHD Data Used for the Forecast
  • Table 9: 6MM, Sources Not Used in the Epidemiological Analysis of GVHD
  • Table 10: 6MM, Diagnosed Incident Cases of HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 11: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 12: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 13: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 14: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 15: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 16: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 17: Product Profile - Methylprednisolone
  • Table 18: Efficacy of Methylprednisolone in GVHD Studies
  • Table 19: SWOT analysis - Methylprednisolone, 2014
  • Table 20: Product Profile - Cyclosporine
  • Table 21: Efficacy of Cyclosporine in GVHD Studies
  • Table 22: SWOT Analysis - Cyclosporine, 2014
  • Table 23: Product Profiles - ATG Therapies
  • Table 24: Efficacy of ATG Therapies in GVHD
  • Table 25: SWOT Analysis - ATG Therapies, 2014
  • Table 26: Product Profile - Biologics - TNFα Inhibitors
  • Table 27: Efficacy of Anti-TNFα Therapies in GVHD
  • Table 28: Product Profiles - Biologics - IL-2Rα (CD25) Inhibitors
  • Table 29: Efficacy of IL-2Rα (CD25) Inhibitor Therapies in GVHD
  • Table 30: Product Profile - Biologics - Co-Stimulatory Blockers
  • Table 31: Efficacy of Co-Stimulatory Blocker Therapies in GVHD
  • Table 32: Product Profile - Other Biologics (Campath/Lemtrada and Rituxan)
  • Table 33: Efficacy of Other Biologic Therapies (Campath/Lemtrada and Rituxan) in GVHD
  • Table 34: Safety Profile - Off-Label Biologics Used in GVHD, 2014
  • Table 35: SWOT Analysis - Biologics - TNFα Inhibitors, 2014
  • Table 36: SWOT Analysis - Biologics - IL-2Rα (CD25) inhibitors, 2014
  • Table 37: SWOT Analysis - Biologics - Co-Stimulatory Blockers, 2014
  • Table 38: SWOT Analysis - Biologics - Others, 2014
  • Table 39: Product Profile - Small Immunosuppressive Molecules - mTOR Inhibitors
  • Table 40: Efficacy of mTOR Inhibitors in GVHD
  • Table 41: Product Profile - Small Immunosuppressive Molecules - SOT Therapies
  • Table 42: Efficacy of SOT Therapies in GVHD
  • Table 43: Product Profile - Small Immunosuppressive Molecules - Anti-Neoplastic Therapies
  • Table 44: Efficacy of Anti-Neoplastic Therapies in GVHD
  • Table 45: Safety Profile - Small Immunosuppressive Molecules
  • Table 46: SWOT Analysis - Small Immunosuppressive Molecules - mTOR Inhibitors, 2014
  • Table 47: SWOT Analysis - Small Immunosuppressive Molecules - SOT Therapies, 2014
  • Table 48: SWOT analysis - Small Immunosuppressive Molecules - Anti-Neoplastic Therapies, 2014
  • Table 49: Unmet Need and Opportunity in GVHD
  • Table 50: Clinical Trial Design of Key Pipeline Drugs for GVHD, July 2014
  • Table 51: GVHD - Late Stage Pipeline, 2013
  • Table 52: Product Profile - Leukotac (inolimomab)
  • Table 53: Efficacy of Leukotac in GVHD
  • Table 54: SWOT Analysis - Leukotac (inolimomab), 2014
  • Table 55: Product Profile - Begedina (BT 5/9)
  • Table 56: Efficacy of Begedina in GVHD
  • Table 57: SWOT Analysis - Begedina (BT 5/9), 2015
  • Table 58: Product Profile - Budenofalk (budesonide)
  • Table 59: SWOT Analysis - Budenofalk, 2014
  • Table 60: Product Profile - ATG-Fresenius (EZ-2053)
  • Table 61: Efficacy of ATG-Fresenius in GVHD (EZ-2053)
  • Table 62: SWOT Analysis - ATG-Fresenius, 2014
  • Table 63: Product Profile - Prochymal (remestemcel-L)
  • Table 64: SWOT Analysis - Prochymal (remestemcel-L), 2014
  • Table 65: Product Profile - MultiStem (modified mesenchymal stem cells)
  • Table 66: SWOT Analysis - MultiStem (modified mesenchymal stem cells)
  • Table 67: Product Profile - Uvadex (Extracorporeal Photophoresis)
  • Table 68: Efficacy of Uvadex in GVHD
  • Table 69: SWOT Analysis - Uvadex (Extracorporeal Photophoresis)
  • Table 70: Product Profile - orBec (beclomethasone dipropionate)
  • Table 71: SWOT Analysis - orBec (beclomethasone proprionate), 2014
  • Table 72: Early-Stage Pipeline Products for GVHD, July 2014
  • Table 73: Clinical Benchmarking for GVHD Prophylaxis, 2014
  • Table 74: Clinical Benchmarking for aGVHD, 2014
  • Table 75: Clinical Benchmarking for cGVHD, 2014
  • Table 76: Commercial Benchmarking for GVHD Prophylaxis, 2014
  • Table 77: Commercial Benchmarking for aGVHD, 2014
  • Table 78: Commercial Benchmarking for cGVHD, 2014
  • Table 79: Top-Line Sales Forecasts ($m) for GVHD, 2013-2023
  • Table 80: Key Events Impacting Sales for GVHD, 2013-2023
  • Table 81: Global GVHD Market - Drivers and Barriers, 2013-2023
  • Table 82: Key Launch Dates, GVHD, 2013-2023
  • Table 83: Key Patent Expiries, GVHD, 2013-2023

List of Figures

  • Figure 1: Schematic of HSCT
  • Figure 2: Schematic Flow Chart of the Derivation of the aGVHD and cGVHD Patient Population in the 6MM
  • Figure 3: 6MM, Diagnosed Incident Cases of HSCTs , Both Sexes, All Ages, N, 2013-2023
  • Figure 4: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 5: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 6: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 7: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, 2013-2023
  • Figure 8: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Figure 9: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Figure 10: Trends in aGVHD Management in the 6MM, 2014
  • Figure 11: Trends in cGVHD Management in the 6MM, 2014
  • Figure 12: Schematic Representation of Unmet Needs
  • Figure 13: An Overview of the GVHD Prophylaxis Clinical Trials, 2015
  • Figure 14: An Overview of the aGVHD Clinical Trials, 2015
  • Figure 15: An Overview of the cGVHD Clinical Trials, 2015
  • Figure 16: Competitive Assessment of GVHD Prophylaxis Off-Label Therapies and Late-Stage Pipeline Agents, 2013-2023
  • Figure 17: Competitive Assessment of aGVHD Off-Label Therapies and Late-Stage Pipeline Agents, 2013-2023
  • Figure 18: Competitive Assessment of cGVHD Off-Label Therapies and Late-Stage Pipeline Agents, 2013-2023
  • Figure 19: Global Sales for GVHD by Region and GVHD Indication, 2013-2023
Back to Top